Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene

Abstract

Dysregulation of the PI3K/Akt/mTOR pathway is one of the most frequent events in human cancer. However, the clinical benefits of PI3K/Akt/mTOR inhibitors have not yet achieved their predicted potential in many of the most prevalent human cancers. Of interest, treatment of Kaposi’s sarcoma (KS) patients with rapamycin provided the first evidence of the antineoplastic activity of mTOR inhibitors in humans, becoming the standard of care for KS arising in renal transplant patients. Thus, the study of KS may provide a unique opportunity to dissect the contribution of specific mTOR downstream targets to cancer development. The KS-associated herpesvirus (KSHV) is the etiological agent for KS, and the KSHV-encoded oncogene viral-G protein-coupled receptor (vGPCR) promotes the potent activation of the PI3K-Akt-mTOR pathway by both direct and paracrine mechanisms. We focused on a direct target of mTOR, EIF4EBP1/2/3 (4EBP), which inhibits the translation of eukaryotic initiation factor 4E (eiF4E)-bound mRNAs. 4EBP phosphorylation by mTOR relieves its inhibitory activity, hence resulting in increased eiF4E-dependent mRNA translation. We developed a paracrine transformation model, recapitulating the cellular composition of KS lesions, in which vGPCR-expressing cells promote the rapid proliferation of endothelial cells, thus expressing KSHV-latent genes by the release of growth factors. Using this model, we show here that the accumulation of dephosphorylated 4EBP in response to rapamycin or by the expression of an mTOR-insensitive mutant of 4EBP1 is sufficient to disrupt the eiF4E function downstream of mTOR to a similar extent than the mTOR catalytic inhibitor Torin2 and to halt KS development. We also provide evidence that eiF4E contributes to paracrine neoplastic, signaling through the release of pro-angiogenic factors that are acting on endothelial cells, expressing KSHV-latent genes. These findings may provide a preclinical platform and the rationale for the development of novel mTOR, inhibiting agents that may selectively disrupt the mTOR-4EBP interaction for the treatment of KS and other tumor lesions, exhibiting hyperactive mTOR pathway function.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Laplante M, Sabatini DM . mTOR signaling in growth control and disease. Cell 2012; 149: 274–293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Engelman JA, Luo J, Cantley LC . The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606–619.

    Article  CAS  PubMed  Google Scholar 

  3. Dann SG, Selvaraj A, Thomas G . mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007; 13: 252–259.

    Article  CAS  PubMed  Google Scholar 

  4. Yanagiya A, Suyama E, Adachi H, Svitkin YV, Aza-Blanc P, Imataka H et al. Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol Cell 2012; 46: 847–858.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909–918.

    Article  CAS  PubMed  Google Scholar 

  6. Dancey J . mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010; 7: 209–219.

    Article  CAS  PubMed  Google Scholar 

  7. Stallone G, Infante B, Grandaliano G, Schena FP, Gesualdo L . Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression. Transpl Int 2008; 21: 825–832.

    Article  PubMed  Google Scholar 

  8. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865–1869.

    Article  CAS  PubMed  Google Scholar 

  9. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003; 3: 23–36.

    Article  CAS  PubMed  Google Scholar 

  10. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317–1323.

    Article  CAS  PubMed  Google Scholar 

  11. Ganem D . KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 2006; 1: 273–296.

    Article  CAS  PubMed  Google Scholar 

  12. Hosseini-Moghaddam SM, Soleimanirahbar A, Mazzulli T, Rotstein C, Husain S . Post renal transplantation Kaposi's sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy. Transpl Infect Dis 2012; 14: 338–345.

    Article  CAS  PubMed  Google Scholar 

  13. Mesri EA, Cesarman E, Boshoff C . Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10: 707–719.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Minchinton AI, Tannock IF . Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583–592.

    Article  CAS  PubMed  Google Scholar 

  15. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006; 10: 133–143.

    Article  CAS  PubMed  Google Scholar 

  16. Vilar E, Perez-Garcia J, Tabernero J . Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011; 10: 395–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Martin D, Galisteo R, Ji Y, Montaner S, Gutkind JS . An NF-kappaB gene expression signature contributes to Kaposi's sarcoma virus vGPCR-induced direct and paracrine neoplasia. Oncogene 2008; 27: 1844–1852.

    Article  CAS  PubMed  Google Scholar 

  18. Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, Sausville EA et al. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci USA 2004; 101: 4821–4826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Benjamin D, Colombi M, Moroni C, Hall MN . Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10: 868–880.

    Article  CAS  PubMed  Google Scholar 

  20. Liu Q, Kang SA, Thoreen CC, Hur W, Wang J, Chang JW et al. Development of ATP-competitive mTOR inhibitors. Methods Mol Biol 2012; 821: 447–460.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gasperini P, Tosato G . Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma. Leukemia 2009; 23: 1867–1874.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Vuiblet V, Birembaut P, Francois A, Cordonnier C, Noel LH, Goujon JM et al. Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrlo Dial Transplant 2012; 27: 411–416.

    Article  CAS  Google Scholar 

  23. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res 2012; 72: 6468–6476.

    Article  CAS  PubMed  Google Scholar 

  24. Gasperini P, Sakakibara S, Tosato G . Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis. J Leukoc Biol 2008; 84: 994–1000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, Duran EM et al. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 2007; 11: 245–258.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cesarman E, Mesri EA, Gershengorn MC . Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? J Exp Med 2000; 191: 417–422.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Vitale-Cross L, Molinolo AA, Martin D, Younis RH, Maruyama T, Patel V et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res 2012; 5: 562–573.

    Article  CAS  Google Scholar 

  28. Bieleski L, Talbot SJ . Kaposi's sarcoma-associated herpesvirus vCyclin open reading frame contains an internal ribosome entry site. J Virol 2001; 75: 1864–1869.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This research was supported by the National Institutes of Health Intramural AIDS-Targeted Antiviral Program and the National Institute of Dental and Craniofacial Research. We apologize to colleagues whose primary research papers may not have been cited due to space constraints.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J S Gutkind.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, D., Nguyen, Q., Molinolo, A. et al. Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene. Oncogene 33, 2405–2412 (2014). https://doi.org/10.1038/onc.2013.193

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.193

Keywords

This article is cited by

Search

Quick links